Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.
Pasquale LombardiMarco FilettiRosa FalconeValeria AltamuraFrancesco Paroni SterbiniEmilio BriaAlessandra FabiDiana GiannarelliGiovanni ScambiaGennaro DanielePublished in: Cancers (2023)
Trophoblast cell surface antigen-2 (Trop-2) is a glycoprotein that was first described as a membrane marker of trophoblast cells and was associated with regenerative abilities. Trop-2 overexpression was also described in several tumour types. Nevertheless, the therapeutic potential of Trop-2 was widely recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. Recently, these efforts have been rewarded with the approval of sacituzumab govitecan from both the Food and Drug Administration (FDA) and European Medicines Agency (EMA), for metastatic triple-negative breast cancer patients. In our work, we briefly summarize the various characteristics of cancer cells overexpressing Trop-2, the pre-clinical activities of specific inhibitors, and the role of anti-Trop-2 therapy in current clinical practice. We also review the ongoing clinical trials to provide a snapshot of the future developments of these therapies.
Keyphrases
- drug administration
- clinical trial
- papillary thyroid
- cell surface
- clinical practice
- stem cells
- squamous cell carcinoma
- current status
- small cell lung cancer
- mesenchymal stem cells
- induced apoptosis
- squamous cell
- emergency department
- cell proliferation
- randomized controlled trial
- cell therapy
- climate change
- smoking cessation
- young adults